Tesamorelin

Tesamorelin Peptide Detailed Overview

Tesamorelin is a highly significant compound within the Growth Hormone axis research bracket, designed to stimulate and analyze the intricate cascades of systemic metabolic regeneration and endocrine pulsing.

Pharmacological Profile

Parameter	Value
Molecular Formula	C211H366N72O67S1
Molecular Weight	4915.6 g/mol
Assay Purity	>98.0%
Appearance	White to off-white powder

Figure 1: Conceptual Binding Mechanism of Tesamorelin

Molecular Methodology

The sequential action framework observed in experimental diagnostics:

1. Acts as a targeted GHRH (Growth Hormone Releasing Hormone) analogue with a trans-3-hexenoic acid group attached.
2. Binds to pituitary receptors to induce natural pulsatile GH generation.
3. Highly selective for generating GH that specifically targets deep visceral fat.
4. Bypasses subcutaneous fat storage and forcefully cleaves lipid bonds.
5. Maintains precise endogenous feedback loops, preventing abnormal IGF-1 spikes.

Figure 2: Empirical Systemic Response Profile

Identified Research Parameters

• Vector Observation: The premier peptide currently researched for extreme visceral adipose reduction.
• Trial Output: Historically utilized to reverse lipidodystrophy in immunocompromised patients (HIV-associated).
• Diagnostic Core: Improves cognitive function parameters in MCI (Mild Cognitive Impairment) studies.

GHRH(1-44) Analogue for Visceral Fat Research

Tesamorelin is a synthetic 44-amino acid GHRH analogue consisting of the full human GHRH(1-44) sequence with a trans-3-hexenoic acid modification at the N-terminus. This modification protects against DPP-4 enzymatic degradation (which cleaves native GHRH between positions 2 and 3 within minutes), extending the half-life sufficiently for once-daily subcutaneous dosing. Tesamorelin is unique among GH-axis peptides as the only one with FDA approval specifically for body composition modification.

1. Tesamorelin binds the GHRH receptor on pituitary somatotrophs, activating Gs/cAMP/PKA signaling identically to native GHRH(1-44).
2. The trans-3-hexenoic acid cap prevents DPP-4 from accessing the Tyr1-Ala2 cleavage site, extending biological half-life to approximately 26 minutes.
3. Pulsatile GH release is augmented by 2–3x above baseline, preserving the physiological pattern of somatotroph secretion.
4. The GH elevation preferentially drives lipolysis in visceral adipose tissue (VAT), which has higher GH receptor density than subcutaneous fat.
5. Tesamorelin does not affect cortisol, prolactin, or thyroid hormone levels at therapeutic doses, confirming somatotroph selectivity.

FDA-Approved Use & Clinical Data

• Egrifta® Approval: FDA approved (2010) for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Dosed at 2 mg SC daily.
• Visceral Fat Reduction: The LIPO-010 trial demonstrated 15% reduction in visceral adipose tissue (CT-measured) at 26 weeks versus 5% increase in placebo, without changes in subcutaneous fat.
• MASH Research: The Theratechnologies-sponsored TERAHEP trial demonstrated tesamorelin significantly reduced hepatic fat fraction (MRI-PDFF) and prevented MASH progression in HIV patients.
• Cognitive Research: A pilot study showed tesamorelin improved executive function and verbal memory in cognitively normal older adults, attributed to GH-mediated neuroprotective effects.
• IGF-1 Monitoring: Tesamorelin increases IGF-1. Protocols recommend monitoring to keep IGF-1 within the age-adjusted upper range. Dose reduction if IGF-1 exceeds upper limit of normal.